Rescue of impaired fracture healing in COX-2-/- mice via activation of prostaglandin E2 receptor subtype 4.
暂无分享,去创建一个
R. Guldberg | E. Schwarz | R. O’Keefe | A. Lin | Xinping Zhang | Alayna E. Loiselle | C. Xie | Bojian Liang | Ming Xue | A. Loiselle
[1] Z. Werb,et al. Matrix Metalloproteinase-9 Facilitates Glial Scar Formation in the Injured Spinal Cord , 2008, The Journal of Neuroscience.
[2] G. Wheeler,et al. Three matrix metalloproteinases are required in vivo for macrophage migration during embryonic development , 2008, Mechanisms of Development.
[3] S. Thibeault,et al. Extracellular Matrix Gene Expression after Vocal Fold Injury in a Rabbit Model , 2008, The Annals of otology, rhinology, and laryngology.
[4] K. Lau,et al. Retroviral‐based gene therapy with cyclooxygenase‐2 promotes the union of bony callus tissues and accelerates fracture healing in the rat , 2008, The journal of gene medicine.
[5] T. Wronski,et al. Effects of Basic Fibroblast Growth Factor and a Prostaglandin E2 Receptor Subtype 4 Agonist on Osteoblastogenesis and Adipogenesis in Aged Ovariectomized Rats , 2007, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[6] S. Narumiya,et al. Prostaglandin E Receptors* , 2007, Journal of Biological Chemistry.
[7] A. M. Simon,et al. Dose and time-dependent effects of cyclooxygenase-2 inhibition on fracture-healing. , 2007, The Journal of bone and joint surgery. American volume.
[8] W. R. Taylor,et al. Impaired Angiogenesis, Early Callus Formation, and Late Stage Remodeling in Fracture Healing of Osteopontin‐Deficient Mice , 2006, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[9] B. Gawronska-Kozak,et al. Matrix metalloproteinase 9 (MMP-9) is upregulated during scarless wound healing in athymic nude mice. , 2006, Matrix biology : journal of the International Society for Matrix Biology.
[10] D. Colleselli,et al. Inhibition of cyclooxygenase (COX)-2 affects endothelial progenitor cell proliferation. , 2006, Experimental cell research.
[11] C. Kirkpatrick,et al. Cyclooxygenases and prostaglandin E2 receptors in growth plate chondrocytes in vitro and in situ – prostaglandin E2 dependent proliferation of growth plate chondrocytes , 2006, Arthritis research & therapy.
[12] S. Baruchel,et al. Inhibition of cyclooxygenase-2 disrupts tumor vascular mural cell recruitment and survival signaling. , 2006, Cancer research.
[13] J. Regan,et al. EP4 Prostanoid Receptor Coupling to a Pertussis Toxin-Sensitive Inhibitory G Protein , 2006, Molecular Pharmacology.
[14] V. Paralkar,et al. A Nonprostanoid EP4 Receptor Selective Prostaglandin E2 Agonist Restores Bone Mass and Strength in Aged, Ovariectomized Rats , 2005, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[15] T. Einhorn. The Science of Fracture Healing , 2005, Journal of orthopaedic trauma.
[16] R. Strieter,et al. Infiltration of COX-2-expressing macrophages is a prerequisite for IL-1 beta-induced neovascularization and tumor growth. , 2005, The Journal of clinical investigation.
[17] J. Regan,et al. Differential Regulation of Phosphorylation of the cAMP Response Element-Binding Protein after Activation of EP2 and EP4 Prostanoid Receptors by Prostaglandin E2 , 2005, Molecular Pharmacology.
[18] J. Bonventre,et al. Cytosolic phospholipase A2alpha regulates induction of brain cyclooxygenase-2 in a mouse model of inflammation. , 2005, American Journal of Physiology. Regulatory Integrative and Comparative Physiology.
[19] N. Kugai,et al. Biphasic Effect of Prostaglandin E2 on Osteoclast Formation in Spleen Cell Cultures: Role of the EP2 Receptor , 2004, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[20] W. R. Taylor,et al. Quantitative microcomputed tomography analysis of collateral vessel development after ischemic injury. , 2004, American journal of physiology. Heart and circulatory physiology.
[21] E. Schwarz,et al. Primary murine limb bud mesenchymal cells in long-term culture complete chondrocyte differentiation: TGF-beta delays hypertrophy and PGE2 inhibits terminal differentiation. , 2004, Bone.
[22] P. Aspenberg. „Differential inhibition of fracture healing by non‐selective and cyclooxygenase‐2 selective non‐steroidal anti‐inflammatory drugs”︁ , 2004, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.
[23] T. Hla,et al. Role of prostaglandin E2-dependent angiogenic switch in cyclooxygenase 2-induced breast cancer progression. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[24] V. Paralkar,et al. A Novel, Non‐Prostanoid EP2 Receptor‐Selective Prostaglandin E2 Agonist Stimulates Local Bone Formation and Enhances Fracture Healing , 2003, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[25] H. Young,et al. Angiogenic effects of prostaglandin E2 are mediated by up-regulation of CXCR4 on human microvascular endothelial cells. , 2003, Blood.
[26] Jill A. Helms,et al. Altered fracture repair in the absence of MMP9 , 2003, Development.
[27] R E Guldberg,et al. Analyzing bone, blood vessels, and biomaterials with microcomputed tomography. , 2003, IEEE engineering in medicine and biology magazine : the quarterly magazine of the Engineering in Medicine & Biology Society.
[28] S. Vukicevic,et al. An EP2 receptor-selective prostaglandin E2 agonist induces bone healing , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[29] Thomas A Einhorn,et al. Fracture healing as a post‐natal developmental process: Molecular, spatial, and temporal aspects of its regulation , 2003, Journal of cellular biochemistry.
[30] M. Genovese,et al. COX‐2 selective NSAID decreases bone ingrowth in vivo , 2002, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.
[31] B. Boyan,et al. Transforming growth factor-beta1 regulation of growth zone chondrocytes is mediated by multiple interacting pathways. , 2002, Biochimica et biophysica acta.
[32] E. Schwarz,et al. Cyclooxygenase-2 regulates mesenchymal cell differentiation into the osteoblast lineage and is critically involved in bone repair. , 2002, The Journal of clinical investigation.
[33] A. M. Simon,et al. Cyclo‐Oxygenase 2 Function Is Essential for Bone Fracture Healing , 2002, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[34] E. Fosslien. Review: molecular pathology of cyclooxygenase-2 in cancer-induced angiogenesis. , 2001, Annals of clinical and laboratory science.
[35] C. Rüegg,et al. NSAIDs inhibit αVβ3 integrin-mediated and Cdc42/Rac-dependent endothelial-cell spreading, migration and angiogenesis , 2001, Nature Medicine.
[36] B. Ashby,et al. Agonist‐induced internalization and mitogen‐activated protein kinase activation of the human prostaglandin EP4 receptor , 2001, FEBS letters.
[37] B. Ashby,et al. Comparison of agonist-induced internalization of the human EP2 and EP4 prostaglandin receptors: role of the carboxyl terminus in EP4 receptor sequestration. , 2000, Molecular pharmacology.
[38] S. Narumiya,et al. The role of prostaglandin E receptor subtypes (EP1, EP2, EP3, and EP4) in bone resorption: an analysis using specific agonists for the respective EPs. , 2000, Endocrinology.
[39] E L Ritman,et al. Restoration of bone mass in the severely osteopenic senescent rat. , 2000, The journals of gerontology. Series A, Biological sciences and medical sciences.
[40] E. Levin,et al. Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: Insight into mechanisms and implications for cancer growth and ulcer healing , 1999, Nature Medicine.
[41] P. Rüegsegger,et al. Direct Three‐Dimensional Morphometric Analysis of Human Cancellous Bone: Microstructural Data from Spine, Femur, Iliac Crest, and Calcaneus , 1999, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[42] B. Boyan,et al. Arachidonic acid directly mediates the rapid effects of 24,25-dihydroxyvitamin D3 via protein kinase C and indirectly through prostaglandin production in resting zone chondrocytes. , 1999, Endocrinology.
[43] Napoleone Ferrara,et al. VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation , 1999, Nature Medicine.
[44] M. Weinreb,et al. The anabolic effect of PGE2 in rat bone marrow cultures is mediated via the EP4 receptor subtype. , 1999, The American journal of physiology.
[45] T A Einhorn,et al. The cell and molecular biology of fracture healing. , 1998, Clinical orthopaedics and related research.
[46] P. Lipsky,et al. Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor: efficacy and safety in two placebo-controlled trials in osteoarthritis and rheumatoid arthritis, and studies of gastrointestinal and platelet effects. , 1998, Arthritis and rheumatism.
[47] Gabriele Bergers,et al. MMP-9/Gelatinase B Is a Key Regulator of Growth Plate Angiogenesis and Apoptosis of Hypertrophic Chondrocytes , 1998, Cell.
[48] B. Boyan,et al. The effect of prostaglandin E2 on costochondral chondrocyte differentiation is mediated by cyclic adenosine 3',5'-monophosphate and protein kinase C. , 1998, Endocrinology.
[49] F. Balkwill,et al. Zymography: a single-step staining method for quantitation of proteolytic activity on substrate gels. , 1997, Analytical biochemistry.
[50] H. Herschman. Prostaglandin synthase 2. , 1996, Biochimica et biophysica acta.
[51] H. Kawaguchi,et al. The role of prostaglandins in the regulation of bone metabolism. , 1995, Clinical orthopaedics and related research.
[52] M. Ågren,et al. Gelatinase activity during wound healing , 1994, The British journal of dermatology.
[53] H. Svanholm,et al. Bone formation induced in an infant by systemic prostaglandin-E2 administration. , 1988, Acta orthopaedica Scandinavica.
[54] S. Kanaoka,et al. Cyclooxygenase-2 and tumor biology. , 2007, Advances in clinical chemistry.
[55] L. Raisz,et al. Prostaglandins: Mechanisms of action and regulation of production in bone , 2005, Osteoporosis International.
[56] 吉田 圭二. Stimulation of bone formation and prevention of bone loss by prostaglandin E EP4 receptor activation , 2002 .
[57] R. Breyer,et al. Prostanoid receptors: subtypes and signaling. , 2001, Annual review of pharmacology and toxicology.
[58] S. Keila,et al. Systemic prostaglandin E2 increases cancellous bone formation and mass in aging rats and stimulates their bone marrow osteogenic capacity in vivo and in vitro. , 2001, The Journal of endocrinology.
[59] A. M. Simon,et al. EFFECTS OF CYCLOOXYGENASE-2 INHIBITORS ON FRACTURE HEALING * , 2001 .
[60] R. Garavito,et al. Cyclooxygenases: structural, cellular, and molecular biology. , 2000, Annual review of biochemistry.
[61] TOR Hildebrand,et al. Quantification of Bone Microarchitecture with the Structure Model Index. , 1997, Computer methods in biomechanics and biomedical engineering.
[62] W. Jee,et al. Long-term anabolic effects of prostaglandin-E2 on tibial diaphyseal bone in male rats. , 1991, Bone and mineral.
[63] T. Einhorn,et al. Production of a standard closed fracture in laboratory animal bone , 1984, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.
[64] R. Breyer,et al. Printed in U.S.A. Copyright © 2000 by The Endocrine Society Knockout of the Murine Prostaglandin EP 2 Receptor Impairs Osteoclastogenesis in Vitro* , 2022 .